ACT-1014-6470

CAT: 0804-HY-157472Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-157472Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ACT-1014-6470 is an orally active, potent, reversible, and selective C5aR1 antagonist. ACT-1014-6470 demonstrates potent inhibition of C5aR1 activation. ACT-1014-6470 can be used in the research of inflammatory diseases[1][2].
CAS Number
[2363082-87-3]
UNSPSC
12352005
Target
Complement System
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C1N(CC2=CC=CC=C2C(F)(F)F)C3=NN(CC(F)(F)C)C=C3CN1C4CCN(C5=C(C)C=CC=C5F)CC4
Molecular Formula
C28H29F6N5O
Molecular Weight
565.55
References & Citations
[1]Sylvie FROIDEVAUX, et al. 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases. WO2019137927A1. WIPO (PCT) . 2019-01-09. |[2]Ort M, et al. First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients. Basic Clin Pharmacol Toxicol. 2022 Aug;131 (2) :114-128.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-138453-01ACT-1016-0707
HY-153240ACT-672125
HY-124071-01ACT-389949
HY-101834-01ACT-462206
HY-119085ACT-281959
HY-108683ACT-335827
HY-135500-01ACT-373898
HY-149055-01ACT-777991
HY-111817-01ACT-451840
HY-U00262ACT 178882

Alternative Products

CatalogName
110050Hsp-1014
sc-23916LRP (1014)
MF-0151345-01CC 1014
sc-23916 ACLRP (1014) AC
sc-23916 FITCLRP (1014) FITC
sc-23916 HRPLRP (1014) HRP
sc-23916 PELRP (1014) PE
YP-W16964-01Human ACT (ACT) ELISA Kit
MBS132402-01Macitentan (ACT 064992; ACT-064992)
MBS3613109-01ACT-389949

Popular Products